Skip to main
NTLA
NTLA logo

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

Intellia Therapeutics (NTLA) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 26%
Hold 42%
Sell 0%
Strong Sell 0%

Bulls say

Intellia Therapeutics's focus on developing CRISPR/Cas9-based therapeutics for genetically defined diseases positions the company favorably within the biotechnology sector, particularly given the potential market impact of treatments for conditions like ATTR amyloidosis and sickle cell disease. The net present value modeling indicates a valuation of $12.22 per share for lonvo-z in hereditary angioedema, reflecting a significant launch probability and anticipated market penetration by 2035, showcasing the potential for revenue growth. Furthermore, projected reductions in operating expenses from $600 million to $150 million by 2034 support a financially sustainable model as the company advances its high-potential pipeline.

Bears say

The negative outlook for Intellia Therapeutics's stock is influenced by reduced market penetration projections for its gene-editing therapies, specifically a decrease from 4.8% to 3.2% for ATTR-CM due to concerns over liver enzyme and bilirubin elevations. The prevailing sentiment is that gene editing is currently out of favor, demonstrated by Intellia's share price declining by 95% from its all-time highs, which raises questions about the competitiveness of its treatments, particularly in comparison to established alternatives like stabilizers and RNAi therapies. Additionally, there are significant risks associated with regulatory approval processes and potential clinical trial failures that could lead to downward revisions of risk-adjusted financial projections for the company.

Intellia Therapeutics (NTLA) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 26% recommend Buy, 42% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Intellia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Intellia Therapeutics (NTLA) Forecast

Analysts have given Intellia Therapeutics (NTLA) a Buy based on their latest research and market trends.

According to 19 analysts, Intellia Therapeutics (NTLA) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Intellia Therapeutics (NTLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.